Delineation of LASIK flaps with prednisolone acetate eyedrops.

We describe the use and safety of prednisolone acetate eyedrops at the end of laser in situ keratomileusis (LASIK) to aid proper positioning of the corneal flap. The LASIK flap is created using the preferred technique. Following laser ablation and flap repositioning, one drop of prednisolone acetate is instilled on the eye. This delineates the flap "gutters" and allows perfect flap positioning and centration. We used this technique in 425 eyes undergoing LASIK for correction of spherocylindrical refractive errors. Flap margins were adequately delineated intraoperatively. The only complication related to the use of the steroid suspension was crystal deposition under the flap in one case which resolved completely in 48 hours.

Patient-perceived pain during laser in situ keratomileusis: comparison of fellow eyes.

PURPOSE: To compare pain scores during laser in situ keratomileusis (LASIK) between first-eye surgery and second-eye surgery. SETTING: Private practice, Beirut, Lebanon. DESIGN: Cohort study. METHODS: Sequential bilateral LASIK was performed between January 2010 and January 2011 by the same surgeon using a Schwind Amaris excimer laser. Hemodynamics and intraocular pressure (IOP) were monitored intraoperatively. Patients graded their pain perception on a 4-point scale after the completion of each eye's surgery. RESULTS: The study enrolled 154 patients. The first surgery was performed in the right eye in 106 patients and in the left eye in 48 patients. Patients reported discomfort during suction (mean pain score 0.80 ± 0.56 [SD]). More pain was reported during second-eye surgery by 74% of patients; 2% reported more pain in the first eye, and 24% reported equal pain in both eyes. The mean pain score was 0.63 ± 0.35 in the first eye and 0.93 ± 0.51 in the second eye (P=.01). Pain was higher during second-eye surgery whether the procedure was started in the right eye or in the left eye. Systolic blood pressure was also higher during second-eye surgery (P=.001). There was no statistically significant difference in diastolic blood pressure, heart rate, IOP, or suction-ring pressure. CONCLUSIONS: Patients had more pain during second-eye LASIK for reasons that are not clear. A psychological explanation or regional sensitization processes are potential factors and should be studied. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.

Comparison of 2 types of intrastromal corneal ring segments for keratoconus.

PURPOSE: To assess the effectiveness and safety of 2 types of 6.0 mm intrastromal corneal ring segments (ICRS) in patients with mild to severe keratoconus. SETTING: Lebanese American University, Beirut, Lebanon. DESIGN: Retrospective comparative case series. METHODS: Eyes had implantation of Intacs SK ICRS (Group 1) or Keraring SI6 ICRS (Group 2). Visual acuity (logMAR), refraction, keratometry, and higher-order aberrations were compared 6 months and 1 year postoperatively. RESULTS: Group 1 comprised 66 eyes and Group 2, 107 eyes. The groups were comparable preoperatively. One-year postoperatively, the mean uncorrected distance visual acuity improved by 0.62 logMAR ± 0.19 (SD) in Group 1 and by 0.67 ± 0.17 logMAR in Group 2 (P=.211). The mean corrected distance visual acuity improved by 0.12 ± 0.11 logMAR and by 0.08 ± 0.13, respectively (P=.301). The spherical equivalent decreased by a mean of 2.80 ± 2.87 D and 2.65 ± 3.00 D, respectively (P=.572). Keratometry (K) flat and K steep decreased by a mean of 1.51 ± 1.57 D and 2.24 ± 1.61 D, respectively, in Group 1 and by 1.10 ± 2.00 D and 1.44 ± 1.64 D, respectively, in Group 2 (P=.667 and P=.184, respectively). Primary coma root mean square decreased by a mean of 1.09 ± 0.66 µm in Group 1 and 0.99 ± 0.72 µm in Group 2 (P=.716). CONCLUSION: Both ICRS models significantly improved visual function in patients with keratoconus, with comparable postoperative profiles and no major complications. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.

Azithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis.

PURPOSE: To assess the efficacy of topical 1.5% azithromycin in the treatment of moderate to severe chronic blepharitis and to compare the efficacy of two different treatment modalities. METHODS: A randomized clinical trial included 67 patients with chronic anterior and/or posterior blepharitis, followed-up for 3 months. Signs and symptoms were graded according to severity. Patients were randomized into two groups: 33 patients in group I and 34 patients in group II. Group I patients were treated with topical 1.5% azithromycin twice a day for three days, and Group II patients were treated with topical 1.5% azithromycin twice a day for three days then at bedtime for the rest of the month. All patients were instructed to apply warm compresses and an eye-friendly soap twice daily. RESULTS: Patients in both groups tolerated the treatment with minimal irritation. A significant improvement in signs and symptoms was noted at the one week follow-up visit. Group II showed a more pronounced and longer-lasting improvement that persisted after three months of follow-up. CONCLUSION: Topical 1.5% azithromycin ophthalmic solution is an effective treatment option for chronic blepharitis. In moderate to severe blepharitis, a one month treatment is safe and shows better improvement than the three-day protocol with no significant relapse until three months of follow-up.

Transepithelial photorefractive keratectomy: clinical results.

PURPOSE: To assess the effectiveness, safety, and comfort of transepithelial photorefractive keratectomy (PRK) using the Amaris laser platform. SETTING: Ophthalmic Consultants of Beirut, Jal-El-Dib, Metn, Lebanon. DESIGN: Comparative case series. METHODS: Myopic eyes with or without astigmatism were treated by transepithelial PRK (study group) and compared with variable-adjusted eyes treated by conventional PRK (control group) during which the epithelium was removed with alcohol. Postoperative pain, epithelial healing time, uncorrected distance visual acuity (UDVA), manifest refraction, and haze were analyzed. RESULTS: The mean subjective postoperative pain score (out of 10, indicating worst pain) at 48 hours was 2.0 in the study group (50 eyes) and 4.5 in the control group (50 eyes) (P=.02). The mean time to complete epithelial healing was 2.5 days ± 0.6 (SD) and 3.7 ± 0.8 days, respectively (P=.01). At 1 week, the UDVA was statistically significantly better in the control group; however, at 3 months, there was no statistically significant difference in UDVA, corrected distance visual acuity, or manifest refraction between the groups. Haze was significantly less in the study group (P<.01). CONCLUSIONS: Transepithelial PRK for mild to moderate myopia with or without astigmatism was safe and easier to perform than conventional PRK, and patients had less pain, less postoperative haze, and a faster healing time. The visual outcomes with the 2 techniques were comparable. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.

Azithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis / Solução oftálmica de azitromicina 1,5%: eficácia e modalidades de tratamento em blefarite crônica

PURPOSE: To assess the efficacy of topical 1.5% azithromycin in the treatment of moderate to severe chronic blepharitis and to compare the efficacy of two different treatment modalities. METHODS: A randomized clinical trial included 67 patients with chronic anterior and/or posterior blepharitis, followed-up for 3 months. Signs and symptoms were graded according to severity. Patients were randomized into two groups: 33 patients in group I and 34 patients in group II. Group I patients were treated with topical 1.5% azithromycin twice a day for three days, and Group II patients were treated with topical 1.5% azithromycin twice a day for three days then at bedtime for the rest of the month. All patients were instructed to apply warm compresses and an eye-friendly soap twice daily. RESULTS: Patients in both groups tolerated the treatment with minimal irritation. A significant improvement in signs and symptoms was noted at the one week follow-up visit. Group II showed a more pronounced and longer-lasting improvement that persisted after three months of follow-up. CONCLUSION: Topical 1.5% azithromycin ophthalmic solution is an effective treatment option for chronic blepharitis. In moderate to severe blepharitis, a one month treatment is safe and shows better improvement than the three-day protocol with no significant relapse until three months of follow-up.

OBJETIVO: Avaliar a eficácia do uso tópico de azitromicina 1,5% no tratamento de blefarite crônica moderada a grave, comparando a eficácia de duas diferentes modalidades de tratamento. MÉTODOS: Um ensaio clínico randomizado incluiu 67 pacientes com blefarite anterior e/ou posterior crônica, acompanhados por três meses. Os sinais e sintomas foram classificados de acordo com a gravidade. Os pacientes foram randomizados em dois grupos: 33 pacientes no grupo I e 34 pacientes no grupo II. Os pacientes do grupo I foram tratados com azitromicina tópica 1,5% duas vezes ao dia durante três dias, e os pacientes do grupo II foram tratados com azitromicina tópica 1,5% duas vezes ao dia durante três dias e, em seguida, ao deitar, durante o resto do mês. Todos os pacientes foram instruídos a aplicarem compressas quentes e higiene palpebral duas vezes ao dia. RESULTADOS: Os pacientes em ambos os grupos toleraram o tratamento com irritação mínima. Melhora significativa dos sinais e sintomas foi observada na visita de uma semana de acompanhamento. Grupo II mostrou uma melhora mais acentuada e mais duradoura que persistiu após três meses de acompanhamento. CONCLUSÕES: A solução de azitromicina oftálmica tópica 1,5% é uma opção eficaz de tratamento para a blefarite crônica. Em blefarite moderada a grave, o tratamento de um mês é seguro e demonstrou melhora acentuada em relação ao protocolo de três dias, sem recidiva significante até três meses de acompanhamento.